

Laura McCullagh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1601552/publications.pdf>

Version: 2024-02-01

34
papers

795
citations

687220

13
h-index

526166

27
g-index

35
all docs

35
docs citations

35
times ranked

966
citing authors

#	ARTICLE	IF	CITATIONS
1	The Utility of a Rapid Review Evaluation Process to a National HTA Agency. <i>Pharmacoeconomics</i> , 2022, 40, 203-214.	1.7	2
2	Disparities in Oral Nutritional Supplement Usage and Dispensing Patterns across Primary Care in Ireland: ONSPres Project. <i>Nutrients</i> , 2022, 14, 338.	1.7	3
3	Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.2	4
4	An investigation of community-dwelling older adults' opinions about their nutritional needs and risk of malnutrition; a scoping review. <i>Clinical Nutrition</i> , 2021, 40, 2936-2945.	2.3	16
5	Characteristics and determinants of high volume dispensing in long-term oral nutritional supplement users in primary care: a secondary analysis. <i>BJGP Open</i> , 2021, 5, BJGPO.2020.0131.	0.9	6
6	Integrating clinical pharmacists within general practice: protocol for a pilot cluster randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e041541.	0.8	4
7	Malnutrition: A Misunderstood Diagnosis by Primary Care Health Care Professionals and Community-Dwelling Older Adults in Ireland. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2021, 121, 2443-2453.	0.4	10
8	Healthcare professionals'™ perceptions of malnutrition management and oral nutritional supplement prescribing in the community: A qualitative study. <i>Clinical Nutrition ESPEN</i> , 2021, 44, 415-423.	0.5	13
9	Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective. <i>Value in Health</i> , 2021, 24, 1402-1406.	0.1	1
10	Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. <i>Value in Health</i> , 2020, 23, 52-60.	0.1	23
11	Transferability of Economic Evaluations of Treatments for Advanced Melanoma. <i>Pharmacoeconomics</i> , 2020, 38, 217-231.	1.7	9
12	Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group. <i>Value in Health</i> , 2020, 23, 1423-1426.	0.1	10
13	Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. <i>BMJ Open</i> , 2020, 10, e035087.	0.8	33
14	A preliminary qualitative study of general practitioners'™ views on malnutrition management and oral nutritional supplementation prescription in the community. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	0.4	0
15	A preliminary qualitative study of nurses'™ and dietitians'™ views on malnutrition management and oral nutritional supplementation prescription in the community. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	0.4	0
16	A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland. <i>European Journal of Health Economics</i> , 2020, 21, 895-901.	1.4	4
17	General practitioners'™ views on malnutrition management and oral nutritional supplementation prescription in the community: A qualitative study. <i>Clinical Nutrition ESPEN</i> , 2020, 36, 116-127.	0.5	29
18	The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations. <i>Medical Decision Making</i> , 2020, 40, 144-155.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017. <i>PharmacoEconomics - Open</i> , 2019, 3, 583-589.	0.9	3
20	VP82 Impact of Evidence Synthesis Methods on Outcome of Economic Evaluation. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 93-94.	0.2	0
21	Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a) Tj ETQq1 1 0.784314 rgBT /Ov Application to Drugs for Cancer. <i>Pharmacoeconomics</i> , 2017, 35, 1177-1185.	1.7	3
22	Policies for biosimilar uptake in Europe: An overview. <i>PLoS ONE</i> , 2017, 12, e0190147.	1.1	153
23	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. <i>Frontiers in Pharmacology</i> , 2016, 7, 305.	1.6	48
24	Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland. <i>Pharmacoeconomics</i> , 2016, 34, 925-937.	1.7	20
25	The Pharmacoeconomic Evaluation Process in Ireland. <i>Pharmacoeconomics</i> , 2016, 34, 1267-1276.	1.7	23
26	The cost of the inpatient management of febrile neutropenia in cancer patients - a micro-costing study in the Irish healthcare setting. <i>European Journal of Cancer Care</i> , 2015, 24, 125-132.	0.7	10
27	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 77-94.	1.3	108
28	Personalizing health care: feasibility and future implications. <i>BMC Medicine</i> , 2013, 11, 179.	2.3	81
29	Dabigatran â€“ a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. <i>Frontiers in Pharmacology</i> , 2013, 4, 39.	1.6	75
30	Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting. <i>Pharmacoeconomics</i> , 2012, 30, 941-959.	1.7	11
31	The Authors's Reply. <i>Pharmacoeconomics</i> , 2010, 28, 784-785.	1.7	0
32	A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etxilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting. <i>Pharmacoeconomics</i> , 2009, 27, 829-846.	1.7	60
33	Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals*. <i>HIV Medicine</i> , 2006, 7, 248-254.	1.0	25
34	Neoadjuvant treatment for malignant and metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 0, , .	1.5	4